NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?

October 4, 2018 Danielle Twigg

 Educational poster presented at ISPOR Meeting, Barcelona, November 2018

Previous Article
RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms
RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms

Next Article
How To Use RWE To Optimize P&R Of New Health Technologies
How To Use RWE To Optimize P&R Of New Health Technologies